Adicet Bio Inc ACET:NASDAQ

Adicet Bio (ACET) said Tuesday the US Food and Drug Administration has granted fast track designation to ADI-001, a CD20-targeted experimental medicine for the treatment of relapsed or refractory B-cell Non-Hodgkin's lymphoma, a type of cancer.

ADI-001 is currently being evaluated in an ongoing early-stage dose escalation trial to determine its safety and tolerability.

The clinical-stage biotechnology company said it expects to report additional data from the early-stage trial of ADI-001 in the first half of 2022.

Shares rose 3.8% in premarket trading on Tuesday.

Price: 16.5, Change: +0.6, Percent Change: +3.77